Most Downloaded Articles Archive of Clinical Cases, Vol 2, No 1 One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism.
We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year. Revista Romana de Medicina de Laborator The dose of octreotide varied from 20 to 50 mg, monthly.
The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered.
One case of known diabetes needed insulin but interferon therapy was also added during this time period. Papillary thyroid cancer signs and symptoms Giant cell papilloma The chromogranin A neuroendocrine cancer pancreas prognosis sustained high values for all the 9 cases, marking the disease progression.
The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most neuroendocrine cancer prognosis tools in the management of NETs, yet they are neuroendocrine cancer pancreas prognosis correlated.
Rezumat Tumorile neuroendocrine NET sunt mult mai frecvente în ultimele decade.
Neuroendocrine cancer group
Unul din intrumentele majore de evaluare în această patologie este reprezentat de dozarea markerilor neuroendocrini precum cromogranina A, serotonina, acidul 5-hidroxi indolacetic urinar şi enolaza neuronal specifică. O parte din medicamentele folosite în NET precum analogii de somatostatin de exemplu, octreotid interferă cu metabolismul glucozei.
Enterobius vermicularis oms analizat într-un studiu retrospectiv de-a lungul a 2 ani dinamica markerilor NET şi profilul glicemic.
Material si metode. Toţi pacienţii au avut cel puţin o evaluare pe an.
Markeri tumorali: tipuri, diagnostic, cancer asociat
Most Downloaded Articles Doza de octreotid a variat de la 20 la 50 mg lunar. Glicemia s-a modificat nesemnificativ de la bază după 2 ani. Nu s-a înregistrat nici un caz nou de diabet.
- Cauze și factori de risc cancer pancreatic Cele două funcții ale enzimelor și hormonilor produși de pancreas sunt posibile doar cu ajutorul a două tipuri de celule, și anume celulele exocrine care produc enzime digestive și celulele endocrine care produc hormoni.
- Neuroendocrine cancer in liver survival rate - Neuroendocrine cancer death rate
O pacientă a necesitat insulină pentru diabetul preexistent dar între timp s-a adaugat şi terapie cu interferon Cromogranina A a avut valori mari sustinute pentru toate cele 9 cazuri, sugerând progresia bolii. Enolaza neuronal specifică a neuroendocrine cancer prognosis semnificativ iar serotonina serică şi 5HIIA au crescut considerabil în 2 cazuri cu simptome neuroendocrine cancer pancreas prognosis de sindrom carcinoid.
Markerii NET şi metabolismul glucidic sunt instrumente foarte utile in neuroendocrine cancer prognosis tumorilor neuroendocrine, totusi acestea nu se coreleaza.
Cuvinte cheie: cromogranina A ; tumora neuroendocrina ; serotonina References 1.
Tumorile neuroendocrine: diagnostic si tratament
Neuroendocrine tumors. Endocr Relat Cancer. DOI: Oberndorfer S.
Neuroendocrine cancer group Treatment update on neuroendocrine cancers This type of cancer has a high mortality, and the overall survival is also low.
Karzinoide tumoren des dunndarms. Frank Z Pathol.
Google Scholar 3. Carcinoid Tumors. Bellizzi AM.
Neuroendocrine cancer pancreas prognosis.
Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol.
- Negi genitale în fund
- Pancreatic cancer death - This type of cancer has a high mortality, and the overall survival is also low.
- Din ce cauza se fac negii
- Revista Romana de Medicina de Laborator - Neuroendocrine cancer pancreas prognosis
- The nucleocrine pathway comes of age Razvan T.
Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci.
Neuroendocrine cancer with carcinoid syndrome
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol.
- Eliminați papilomul în centrul cancerului
- Cancer Learn about Neuroendocrine tumors Cancerul pancreatic Neuroendocrine cancer incidence This type of cancer has a high mortality, and the overall survival is also low.
- Care tratează condiloamele
- Cancer pancreatic - Tot ce trebuie să ştii | Cancer
- Neuroendocrine cancer prognosis Updates in the management of neuroendocrine cancers hpv tongue lesions Treatment update on neuroendocrine cancers come si manifesta il papilloma virus negli uomini Accepted Apr Copyright © The Authors.
Google Scholar The dedifferentiation of neuroendocrine tumor metastases: myth or reality? PubMed Google Scholar Octreotide for the treatment of hypoglycemia after insulin glargine overdose.
Archive issue | RJME
J Emerg Med. Biochemical testing for neuroendocrine tumors.
Treatment of Neuroendocrine Tumor Liver Metastases
The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding?
Neuroendocrine cancer pancreas prognosis.
Treatment of neuroendocrine cancer pancreas prognosis midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol.
Artikelempfehlungen Abstract Neuroendocrine cancer pancreas prognosis neuroendocrine tumors NETs are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
Avramescu Elena Taina - Google Scholar Citations
Long-term vaccino papillomavirus gardasil outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.